TY  - JOUR
AU  - Wansch, Katharina
AU  - Schneider, François
AU  - Dölvers, Florian
AU  - Kühn, Anna
AU  - Dragomir, Mihnea P
AU  - Joosten, Maria
AU  - Hilfenhaus, Georg
AU  - Vecchione, Loredana
AU  - Felsenstein, Matthäus
AU  - Lerchbaumer, Markus
AU  - Jürgensen, Christian
AU  - Bahra, Marcus
AU  - Duwe, Gregor
AU  - Schäfer, Reinhold
AU  - Stintzing, Sebastian
AU  - Keilholz, Ulrich
AU  - Neumann, Christopher C M
AU  - Pelzer, Uwe
TI  - Identifying Factors of Organoid Establishment in Pancreatic Cancer: A Prospective Observational Study.
JO  - Cancer medicine
VL  - 15
IS  - 1
SN  - 2045-7634
CY  - Hoboken, NJ
PB  - Wiley
M1  - DKFZ-2026-00001
SP  - e71490
PY  - 2026
N1  - #DKTKZFB26#
AB  - Patient-derived organoid (PDO) models have emerged as critical tools in pancreatic ductal adenocarcinoma (PDAC) research and are used as surrogates for studying the individual's tumor biology. Still, PDO-based concepts for direct clinical application remain challenging. In this prospective observational trial (OrgaPanCCC-01), we aim to address clinical feasibility, identify predictive factors for PDO establishment, and assess the prognostic potential of PDO establishment for patient's survival.Samples for PDO generation were prospectively collected via endoscopy, surgery, and transcutaneous punch biopsy, or from ascites. Patients were followed up for a median time of 14.6 months. We evaluated the clinical feasibility by determining the PDO establishment rate and the time required for establishment. Uni- and multivariate analyses were performed to examine the effect of clinical and sample characteristics on PDO establishment. For the predictive and prognostic potential, PDO establishment was correlated to the patients' disease-free (DFS), progression-free (PFS) and overall survival (OS).Between 2021 and 2023, 75 patients were enrolled with radiologically suspected PDAC at the Charité Universitätsmedizin Berlin and at the Waldfriede Krankenhaus Berlin. PDAC was confirmed in 62 patients (83
KW  - Humans
KW  - Pancreatic Neoplasms: pathology
KW  - Pancreatic Neoplasms: mortality
KW  - Pancreatic Neoplasms: therapy
KW  - Male
KW  - Female
KW  - Organoids: pathology
KW  - Prospective Studies
KW  - Middle Aged
KW  - Aged
KW  - Carcinoma, Pancreatic Ductal: pathology
KW  - Carcinoma, Pancreatic Ductal: mortality
KW  - Prognosis
KW  - Feasibility Studies
KW  - Adult
KW  - Aged, 80 and over
KW  - functional precision medicine (Other)
KW  - pancreatic ductal adenocarcinoma (Other)
KW  - patient‐derived organoids (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41469727
C2  - pmc:PMC12753581
DO  - DOI:10.1002/cam4.71490
UR  - https://inrepo02.dkfz.de/record/307496
ER  -